FDA Approves Dalfampridine to Improve Walking in Adults With MS
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Dalfampridine to Improve Walking in Adults With MS

ROCKVILLE, Md -- January 24, 2010 -- The US Food and Drug Administration (FDA) has approved dalfampridine (Ampyra) extended release tablets to improve walking in patients with multiple sclerosis (MS).

In clinical trials, patients treated with dalfampridine had faster walking speeds than those treated with a placebo.

“Trouble with walking is one of the most debilitating problems people with MS face,” said Russell Katz, MD, Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research, Rockville, Maryland.

Dalfampridine, when given at doses greater than that recommended (10 mg twice a day), can cause seizures.

The most common adverse reactions reported by patients taking dalfampridine in clinical trials include urinary tract infection, insomnia, dizziness, headache, nausea, weakness, back pain, balance disorder, swelling in the nose or throat, constipation, diarrhoea, indigestion, throat pain, and burning, tingling or itching of skin.

Dalfampridine should not be used in patients with moderate to severe kidney disease. In these patients, blood levels with the drug approach those associated with the occurrence of seizures.

SOURCE: US Food and Drug Administration

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities